Pemigatinib
- Generic Name
- Pemigatinib
- Brand Names
- Pemazyre
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F2N5O4
- CAS Number
- 1513857-77-6
- Unique Ingredient Identifier
- Y6BX7BL23K
- Background
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide varie...
- Indication
Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
...
- Associated Conditions
- Refractory Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Relapsed Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 201
- Registration Number
- NCT02393248
- Locations
- 🇺🇸
Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.